SI3191504T1 - Ezrine-derived peptides and their pharmaceutical compositions - Google Patents

Ezrine-derived peptides and their pharmaceutical compositions Download PDF

Info

Publication number
SI3191504T1
SI3191504T1 SI201630027T SI201630027T SI3191504T1 SI 3191504 T1 SI3191504 T1 SI 3191504T1 SI 201630027 T SI201630027 T SI 201630027T SI 201630027 T SI201630027 T SI 201630027T SI 3191504 T1 SI3191504 T1 SI 3191504T1
Authority
SI
Slovenia
Prior art keywords
peptide
pharmaceutical composition
amino acid
seq
effective amount
Prior art date
Application number
SI201630027T
Other languages
English (en)
Slovenian (sl)
Inventor
Rupert Holms
Ravshan Ataullakhanov
Rustam Ataullakhanov
Khachik Sayadyan
Original Assignee
Nearmedic International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nearmedic International Limited filed Critical Nearmedic International Limited
Publication of SI3191504T1 publication Critical patent/SI3191504T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4735—Villin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI201630027T 2015-06-01 2016-06-01 Ezrine-derived peptides and their pharmaceutical compositions SI3191504T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2015120667 2015-06-01
PCT/EP2016/062336 WO2016193285A1 (en) 2015-06-01 2016-06-01 Ezrin-derived peptides and pharmaceutical compositions thereof
EP16728271.4A EP3191504B1 (en) 2015-06-01 2016-06-01 Ezrin-derived peptides and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
SI3191504T1 true SI3191504T1 (en) 2018-04-30

Family

ID=56117690

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630027T SI3191504T1 (en) 2015-06-01 2016-06-01 Ezrine-derived peptides and their pharmaceutical compositions

Country Status (26)

Country Link
US (1) US9682140B2 (zh)
EP (1) EP3191504B1 (zh)
JP (1) JP6721419B2 (zh)
KR (1) KR101842978B1 (zh)
CN (1) CN106188267B (zh)
AU (1) AU2016203656B2 (zh)
BR (1) BR102016012501A2 (zh)
CA (1) CA2931875C (zh)
CY (1) CY1120501T1 (zh)
DK (1) DK3191504T3 (zh)
ES (1) ES2660894T3 (zh)
GB (1) GB2546439B (zh)
HR (1) HRP20180560T1 (zh)
HU (1) HUE038737T2 (zh)
LT (1) LT3191504T (zh)
MA (1) MA39421A (zh)
MD (1) MD3191504T2 (zh)
ME (1) ME03033B (zh)
MX (1) MX2016007122A (zh)
PL (1) PL3191504T3 (zh)
PT (1) PT3191504T (zh)
RS (1) RS57067B1 (zh)
SG (1) SG10201604401UA (zh)
SI (1) SI3191504T1 (zh)
WO (1) WO2016193285A1 (zh)
ZA (1) ZA201603723B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
CN106596977B (zh) * 2017-02-08 2018-06-08 南京医科大学第一附属医院 ezrin在制备哮喘诊断试剂中的应用
WO2021198346A2 (en) 2020-04-01 2021-10-07 Dr. Nesselhut Besitzgesellschaft Mbh Ezrin peptide 1 for use in a method of treating covid-19
JP2024511660A (ja) 2021-03-31 2024-03-14 パンタファルム・アー・ゲー ポストｃｏｖｉｄ－１９を治療する方法における使用のためのエズリンペプチド１

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
GB0301879D0 (en) 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
WO2007060440A2 (en) 2005-11-23 2007-05-31 Regent Research L.L.P. The use of peptides in anti-ulcer therapy

Also Published As

Publication number Publication date
AU2016203656B2 (en) 2020-02-06
LT3191504T (lt) 2018-04-10
CN106188267A (zh) 2016-12-07
GB2546439A (en) 2017-07-19
KR101842978B1 (ko) 2018-03-29
GB2546439B (en) 2020-08-26
US9682140B2 (en) 2017-06-20
WO2016193285A1 (en) 2016-12-08
RS57067B1 (sr) 2018-06-29
ZA201603723B (en) 2019-03-27
KR20160141673A (ko) 2016-12-09
JP2017025055A (ja) 2017-02-02
HRP20180560T1 (hr) 2018-05-04
BR102016012501A2 (pt) 2020-04-28
HUE038737T2 (hu) 2018-11-28
JP6721419B2 (ja) 2020-07-15
MA39421A (fr) 2017-07-19
NZ720748A (en) 2023-09-29
AU2016203656A1 (en) 2016-12-15
SG10201604401UA (en) 2017-01-27
CY1120501T1 (el) 2019-07-10
CA2931875C (en) 2022-06-21
GB201705990D0 (en) 2017-05-31
CN106188267B (zh) 2020-11-06
MX2016007122A (es) 2017-01-25
ME03033B (me) 2018-10-20
ES2660894T3 (es) 2018-03-26
MD3191504T2 (ro) 2018-04-30
DK3191504T3 (en) 2018-04-30
PL3191504T3 (pl) 2018-08-31
US20160346383A1 (en) 2016-12-01
EP3191504B1 (en) 2018-01-17
PT3191504T (pt) 2018-04-16
EP3191504A1 (en) 2017-07-19
CA2931875A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
SI3191504T1 (en) Ezrine-derived peptides and their pharmaceutical compositions
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
IL262805B2 (en) CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death
HRP20140586T1 (hr) Peptidi za lijeäśenje beta-amiloidoze
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
JP2013509432A5 (zh)
JP2018512124A5 (zh)
JP2016516734A5 (zh)
RU2014140231A (ru) Антимикробные пептиды
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
BR112018070819A2 (pt) peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo
Teixeira et al. In vivo antimicrobial evaluation of an alanine-rich peptide derived from Pleuronectes americanus
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
JP2017025055A5 (zh)
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
RU2016121688A (ru) Пептиды производные эзрина и фармацевтические композиции на их основе
JP2018529625A5 (zh)
JP2019506840A5 (zh)
RU2016131195A (ru) Способ лечения инфекционных заболеваний с использованием композиции, включающей полученный из плазмы иммуноглобулин М (IgM)
EA202092447A1 (ru) Обратная пептидная вакцина
KR20140070597A (ko) 병원균을 조절하기 위한 아미노산 서열
WO2018231058A3 (en) ANTIMICROBIAL PEPTIDES AND THEIR MIXTURES HAVING ANTIMICROBIAL ACTIVITY AGAINST NEGATIVE GRAM PATHOGENS
RU2012100241A (ru) Лечение хориоидальной неоваскуляризации с помощью вакцин